Akso Health Group (AHG)
Healthcare · NCM
Price as at 2 Oct 2026, 01:29 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Akso Health Group trades at $1.02, which is 41% above the $0.60 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 14 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
AHG dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2018 | $1.20 | 1 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
About Akso Health Group
Akso Health Group, together with its subsidiaries, operates a social e-commerce mobile platform in the People's Republic of China. It operates Xiaobai Maimai App, a social e-commerce mobile platform that offers food and beverage products, wine, cosmetic products, fashion and apparel, entertainment, housewares, home appliances, and cost-saving promotions at petrol gas stations. The company also sells medical devices, such as defibrillators and anesthesia laryngoscopes. In addition, it provides health treatment, consultancy support, and marketing promotion services, as well as trading and technological promotion services and import and export. The company was formerly known as Xiaobai Maimai Inc. and changed its name to Akso Health Group in December 2021. Akso Health Group was founded in 2014 and is headquartered in Qingdao, China.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
AHG passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
2 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$105.7K · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$68.6K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
AHG peers
The largest companies in the same industry (Medical Distribution), then in the same sector.
- COR Cencora, Inc.
- EBO.AX EBOS Group Limited
- EMPG Empro Group Inc.
- NOVO-B.CO Novo Nordisk
- LLY Eli Lilly and Company
- JNJ Johnson & Johnson
- ABBV AbbVie Inc.
- MRK Merck & Co., Inc.
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Akso Health Group (AHG) undervalued?
Against our fair value estimate of $0.60, AHG at $1.02 is 41% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own AHG?
2 of the institutions we track reported a position in AHG in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its AHG data?
Fundamentals for AHG come from company filings and exchange data, as listed on NCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 2 Oct 2026, 01:29 UTC and is delayed. Our data quality score for this company is 83/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for AHG, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.